OSLO, 31st May 2023: The Annual General Meeting of EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), will be held as a virtual meeting at 10:30 CEST on 9th June 2023.
The notice of the Annual General Meeting with Attendance/Proxy forms, including the Board of Directors' proposed resolutions for the items listed on the agenda. The documents are also available at www.exact-tx.com. The deadline for receiving proxies or attendance registration is 7th June 2023 at 12:00 CEST.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com
John M. Edminson, CFO
EXACT Therapeutics
Email: john.edminson@exact-tx.com
About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drug targeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com